Structural basis for ASPP2 recognition by the tumor suppressor p73

Journal of Molecular Biology

Volumn 423, Issue 4, 2012, Pages 515-527

  Canning, Peter ^a   Von Delft, Frank ^a   Bullock, Alex N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

53BP2; DNA damage; mutant p53; TP73; transactivation

Indexed keywords

ANKYRIN; ASPP2 PROTEIN; PROTEIN P53; PROTEIN P73; PROTEIN SH3; PROTEIN VARIANT; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DNA CONFORMATION; DNA PROTEIN COMPLEX; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

EID: 84867263844     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.08.005     Document Type: Article

References (61)

1. F. Murray-Zmijewski, D.P. Lane, and J.C. Bourdon p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress Cell Death Differ. 13 2006 962 972
2. T. Stiewe The p53 family in differentiation and tumorigenesis Nat. Rev. Cancer 7 2007 165 168
3. E.R. Flores, K.Y. Tsai, D. Crowley, S. Sengupta, A. Yang, F. McKeon, and T. Jacks p63 and p73 are required for p53-dependent apoptosis in response to DNA damage Nature 416 2002 560 564
4. M.P. DeYoung, and L.W. Ellisen p63 and p73 in human cancer: defining the network Oncogene 26 2007 5169 5183
5. L.A. Donehower, M. Harvey, B.L. Slagle, M.J. McArthur, C.A. Montgomery Jr, J.S. Butel, and A. Bradley Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours Nature 356 1992 215 221
6. J.M. Varley Germline TP53 mutations and Li-Fraumeni syndrome Hum. Mutat. 21 2003 313 320
7. A. Yang, R. Schweitzer, D.Q. Sun, M. Kaghad, N. Walker, and R.T. Bronson p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development Nature 398 1999 714 718
8. A. Yang, N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, and J. Bonnin p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours Nature 404 2000 99 103
9. C.H. Arrowsmith Structure and function in the p53 family Cell Death Differ. 6 1999 1169 1173
10. G. Melino, V. De Laurenzi, and K.H. Vousden p73: friend or foe in tumorigenesis Nat. Rev. Cancer 2 2002 605 615
11. G. Melino, X. Lu, M. Gasco, T. Crook, and R.A. Knight Functional regulation of p73 and p63: development and cancer Trends Biochem. Sci. 28 2003 663 670
12. M.T. Wilhelm, A. Rufini, M.K. Wetzel, K. Tsuchihara, S. Inoue, and R. Tomasini Isoform-specific p73 knockout mice reveal a novel role for Delta Np73 in the DNA damage response pathway Genes Dev. 24 2010 549 560
13. R. Tomasini, K. Tsuchihara, M. Wilhelm, M. Fujitani, A. Rufini, and C.C. Cheung TAp73 knockout shows genomic instability with infertility and tumor suppressor functions Genes Dev. 22 2008 2677 2691
14. C.A. Jost, M.C. Marin, and W.G. Kaelin Jr p73 is a simian [correction of human] p53-related protein that can induce apoptosis Nature 389 1997 191 194
15. J. Zawacka-Pankau, A. Kostecka, A. Sznarkowska, E. Hedstrom, and A. Kawiak p73 tumor suppressor protein A close relative of p53 not only in structure but also in anti-cancer approach? Cell Cycle 9 2010 720 728
16. W. Wang, S.H. Kim, and W.S. El-Deiry Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts Proc. Natl Acad. Sci. USA 103 2006 11003 11008
17. J.E. Kravchenko, G.V. Ilyinskaya, P.G. Komarov, L.S. Agapova, D.V. Kochetkov, and E. Strom Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway Proc. Natl Acad. Sci. USA 105 2008 6302 6307
18. H.S. Bell, C. Dufes, J. O'Prey, D. Crighton, D. Bergamaschi, and X. Lu A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo J. Clin. Invest. 117 2007 1008 1018
19. L.M. Lau, J.K. Nugent, X. Zhao, and M.S. Irwin HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function Oncogene 27 2008 997 1003
20. H. Katayama, J. Wang, W. Treekitkarnmongkol, H. Kawai, K. Sasai, and H. Zhang Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73 Cancer Cell 21 2012 196 211
21. A.A. Dar, A. Belkhiri, J. Ecsedy, A. Zaika, and W. El-Rifai Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells Cancer Res. 68 2008 8998 9004
22. C.F. Cheok, N. Kua, P. Kaldis, and D.P. Lane Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53 Cell Death Differ. 17 2010 1486 1500
23. Y. Samuels-Lev, D.J. O'Connor, D. Bergamaschi, G. Trigiante, J.K. Hsieh, and S. Zhong ASPP proteins specifically stimulate the apoptotic function of p53 Mol. Cell 8 2001 781 794
24. D. Bergamaschi, Y. Samuels, B. Jin, S. Duraisingham, T. Crook, and X. Lu ASPP1 and ASPP2: common activators of p53 family members Mol. Cell. Biol. 24 2004 1341 1350
25. S. Gorina, and N.P. Pavletich Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2 Science 274 1996 1001 1005
26. M.A. Larkin, G. Blackshields, N.P. Brown, R. Chenna, P.A. McGettigan, and H. McWilliam Clustal W and clustal X version 2.0 Bioinformatics 23 2007 2947 2948
27. Y.J. Cho, S. Gorina, P.D. Jeffrey, and N.P. Pavletich Crystal structure of a P53 tumor-suppressor DNA complex - understanding tumorigenic mutations Science 265 1994 346 355
28. N.A. Baker, D. Sept, S. Joseph, M.J. Holst, and J.A. McCammon Electrostatics of nanosystems: application to microtubules and the ribosome Proc. Natl Acad. Sci. USA 98 2001 10037 10041
29. D.H. Kim, J.K. Kundu, and Y.J. Surh Redox modulation of p53: mechanisms and functional significance Mol. Carcinog. 50 2011 222 234
30. A.N. Bullock, J. Henckel, and A.R. Fersht Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy Oncogene 19 2000 1245 1256
31. A.N. Bullock, J. Henckel, B.S. DeDecker, C.M. Johnson, P.V. Nikolova, and M.R. Proctor Thermodynamic stability of wild-type and mutant p53 core domain Proc. Natl Acad. Sci. USA 94 1997 14338 14342
32. Y. Huyen, P.D. Jeffrey, W.B. Derry, J.H. Rothman, N.P. Pavletich, E.S. Stavridi, and T.D. Halazonetis Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1 Structure 12 2004 1237 1243
33. E. Natan, and A.C. Joerger Structure and kinetic stability of the p63 tetramerization domain J. Mol. Biol. 415 2012 503 513
34. A.C. Joerger, S. Rajagopalan, E. Natan, D.B. Veprintsev, C.V. Robinson, and A.R. Fersht Structural evolution of p53, p63, and p73: implication for heterotetramer formation Proc. Natl Acad. Sci. USA 106 2009 17705 17710
35. D. Coutandin, F. Lohr, F.H. Niesen, T. Ikeya, T.A. Weber, and B. Schafer Conformational stability and activity of p73 require a second helix in the tetramerization domain Cell Death Differ. 16 2009 1582 1589
36. M. Lokshin, Y. Li, C. Gaiddon, and C. Prives p53 and p73 display common and distinct requirements for sequence specific binding to DNA Nucleic Acids Res. 35 2007 340 352
37. T. Brandt, M. Petrovich, A.C. Joerger, and D.B. Veprintsev Conservation of DNA-binding specificity and oligomerisation properties within the p53 family BMC Genomics 10 2009 628
38. C. Chen, N. Gorlatova, Z. Kelman, and O. Herzberg Structures of p63 DNA binding domain in complexes with half-site and with spacer-containing full response elements Proc. Natl Acad. Sci. USA 108 2011 6456 6461
39. S. Patel, T.T. Bui, A.F. Drake, F. Fraternali, and P.V. Nikolova The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding Biochemistry 47 2008 3235 3244
40. R.A. Robinson, X. Lu, E.Y. Jones, and C. Siebold Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73 Structure 16 2008 259 268
41. H. Tidow, D.B. Veprintsev, S.M. Freund, and A.R. Fersht Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2) J. Biol. Chem. 281 2006 32526 32533
42. S. Patel, R. George, F. Autore, F. Fraternali, J.E. Ladbury, and P.V. Nikolova Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax Nucleic Acids Res. 36 2008 5139 5151
43. J. Ahn, I.J. Byeon, C.H. Byeon, and A.M. Gronenborn Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins J. Biol. Chem. 284 2009 13812 13822
44. E. Krissinel, and K. Henrick Inference of macromolecular assemblies from crystalline state J. Mol. Biol. 372 2007 774 797
45. D. Jozic, N. Cardenes, Y.L. Deribe, G. Moncalian, D. Hoeller, and Y. Groemping Cbl promotes clustering of endocytic adaptor proteins Nat. Struct. Mol. Biol. 12 2005 972 979
46. W. Lilyestrom, M.G. Klein, R. Zhang, A. Joachimiak, and X.S. Chen Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor Genes Dev. 20 2006 2373 2382
47. Collaborative Computational Project Number 4 The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 50 1994 760 763
48. A.G.W. Leslie, and H.R. Powell Processing diffraction data with Mosflm R.J. Read, J.L. Sussman, Evolving Methods for Macromolecular Crystallography 2007 Springer-Verlag New York, NY 41 51
49. P. Evans Scaling and assessment of data quality Acta Crystallogr., Sect. D: Biol. Crystallogr. 62 2006 72 82
50. A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, and R.J. Read Phaser crystallographic software J. Appl. Crystallogr. 40 2007 658 674
51. Y. Wang, A. Rosengarth, and H. Luecke Structure of the human p53 core domain in the absence of DNA Acta Crystallogr., Sect. D: Biol. Crystallogr. 63 2007 276 281
52. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 2004 2126 2132
53. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 53 1997 240 255
54. J. Painter, and E.A. Merritt Optimal description of a protein structure in terms of multiple groups undergoing TLS motion Acta Crystallogr., Sect. D: Biol. Crystallogr. 62 2006 439 450
55. W. Kabsch XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 66 2010 125 132
56. K.Y. Zhang, K. Cowtan, and P. Main Combining constraints for electron-density modification Methods Enzymol. 277 1997 53 64
57. K. Cowtan Fitting molecular fragments into electron density Acta Crystallogr., Sect. D: Biol. Crystallogr. 64 2008 83 89
58. K. Cowtan The Buccaneer software for automated model building. 1. Tracing protein chains Acta Crystallogr., Sect. D: Biol. Crystallogr. 62 2006 1002 1011
59. G.B.E. Bricogne, M. Brandl, C. Flensburg, P. Keller, W. Paciorek, and P.S.A. Roversi BUSTER version 2.10.0 edit 2011 Global Phasing Ltd. Cambridge, United Kingdom
60. O.S. Smart, M. Brandl, C. Flensburg, P. Keller, W. Paciorek, and C. Vonrhein Refinement with Local Structure Similarity Restraints (LSSR) enables exploitation of information from related structures and facilitates use of NCS Abstr. Annu. Meet. Am. Crystallogr. Assoc., Abstract. TP139 2008 117
61. Schrödinger LLC. (Version 1.2r3pre). The PyMOL Molecular Graphics System.